Reclast and Clarinex drug interactions - a phase IV clinical study of FDA data

Summary:

Drug interactions are reported among people who take Reclast (zoledronic acid) and Clarinex (desloratadine). Common drug interactions include pain among females and arthralgia among males.

The phase IV clinical study analyzes what interactions people have when they take Reclast and Clarinex. It is created by eHealthMe based on reports of 17 people who take the same drugs from the FDA, and is updated regularly.

What is Reclast?

Reclast has active ingredients of zoledronic acid. It is often used in osteoporosis. eHealthMe is studying from 15,774 Reclast users. Check the latest studies of Reclast.

What is Clarinex?

Clarinex has active ingredients of desloratadine. It is often used in allergies. eHealthMe is studying from 6,463 Clarinex users. Check the latest studies of Clarinex.



On Jul, 16, 2026

17 people who take Reclast and Clarinex together, and have interactions are studied.

Reclast and Clarinex drug interactions.

What are the common drug interactions of Reclast and Clarinex, by gender? *:

female:

  1. Pain
  2. Arthralgia (joint pain)
  3. Femur fracture
  4. Low turnover osteopathy (slow removal of old bone and its replacement by new bone)
  5. Stress fracture (fracture of a bone caused by repeated (rather than sudden) mechanical stress)
  6. Bone disorder
  7. Fracture displacement
  8. Fracture nonunion (permanent failure of healing following a broken bone)
  9. Groin pain
  10. Mobility decreased (ability to move is reduced)

male:

  1. Arthralgia (joint pain)
  2. Bone disorder
  3. Mass
  4. Mobility decreased (ability to move is reduced)
  5. Monoparesis (one limb is very weak, but not completely paralyzed)
  6. Muscle injury
  7. Osteoporotic fracture (fracture due to weak bone)
  8. Pain
  9. Pathological fracture (broken bone caused by disease)
  10. Sepsis (a severe blood infection that can lead to organ failure and death)

What are the common drug interactions of Reclast and Clarinex, by age (0-1 to 60+)? *:

0-1:

n/a

2-9:

n/a

10-19:

n/a

20-29:

n/a

30-39:

  1. Osteoporotic fracture (fracture due to weak bone)
  2. Pain
  3. Pathological fracture (broken bone caused by disease)
  4. Sepsis (a severe blood infection that can lead to organ failure and death)
  5. Stress fracture (fracture of a bone caused by repeated (rather than sudden) mechanical stress)
  6. Arthralgia (joint pain)
  7. Bone disorder
  8. Dysstasia (difficulty in standing)
  9. Femur fracture
  10. Fracture delayed union (delayed cure of broken bone)

40-49:

  1. Arthralgia (joint pain)
  2. Bone pain
  3. Constipation
  4. Diarrhoea
  5. Eye pain
  6. Fatigue (feeling of tiredness)
  7. Headache (pain in head)
  8. Infusion related reaction
  9. Insomnia (sleeplessness)
  10. Migraine (headache)

50-59:

  1. Femur fracture
  2. Low turnover osteopathy (slow removal of old bone and its replacement by new bone)
  3. Stress fracture (fracture of a bone caused by repeated (rather than sudden) mechanical stress)
  4. Arthralgia (joint pain)
  5. Bone disorder
  6. Fracture displacement
  7. Fracture nonunion (permanent failure of healing following a broken bone)
  8. Groin pain
  9. Mobility decreased (ability to move is reduced)
  10. Osteoporotic fracture (fracture due to weak bone)

60+:

  1. Pain
  2. Dizziness
  3. Bronchial hyperreactivity
  4. Chills (felling of cold)
  5. Dry throat
  6. Dysphonia (speech disorder attributable to a disorder of phonation)
  7. Dyspnoea (difficult or laboured respiration)
  8. Dystonia (abnormal muscle tone)
  9. Dysuria (painful or difficult urination)
  10. Gait disturbance

What are the existing conditions these people have? *

  1. Osteoporosis Post-Menopausal (weak bone with possibility to break after stopped menstrual cycles): 2 people, 11.76%
  2. Narcolepsy (brain's inability to regulate sleep-wake cycles normally): 2 people, 11.76%
  3. Rheumatoid Arthritis (a chronic progressive disease causing inflammation in the joints): 1 person, 5.88%
  4. Indigestion: 1 person, 5.88%
  5. Hypertonic Bladder (bladder-storage function that causes a sudden urge to urinate): 1 person, 5.88%
  6. Hypersensitivity: 1 person, 5.88%
  7. Drowsiness: 1 person, 5.88%
  8. Depression: 1 person, 5.88%
  9. Crohn's Disease (a condition that causes inflammation of the gastrointestinal tract): 1 person, 5.88%
  10. Cataplexy (loss of muscle tone accompanied by full conscious awareness): 1 person, 5.88%

* Approximation only. Some reports may have incomplete information.

Do you take Reclast and Clarinex?

- Personalize this study to your gender, age, symptoms and drugs
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously



Related studies:

Effectiveness of, side effects of, and alternative drugs to the 2 drugs:

Browse all drug interactions of Reclast and Clarinex:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Sub-studies by gender and age:

Female: 0-1 2-9 10-19 20-29 30-39 40-49 50-59 60+

Male: 0-1 2-9 10-19 20-29 30-39 40-49 50-59 60+

Browse all side effects of Reclast:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all side effects of Clarinex:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all interactions between Reclast and drugs from A to Z:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all interactions between Clarinex and drugs from A to Z:

a b c d e f g h i j k l m n o p q r s t u v w x y z

How the study uses the data?

The study uses data from the FDA. It is based on zoledronic acid and desloratadine (the active ingredients of Reclast and Clarinex, respectively), and Reclast and Clarinex (the brand names). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.



Recent studies on eHealthMe: